Education
About Us
Working with TipRanks
Follow Us
Fouad Namouni Insider Profile
4 Followers
Fouad Namouni, Director at Aprea Therapeutics, holds 0.00 shares in Blueprint Medicines (Ticker: BPMC), holds 4.61K shares in Aprea Therapeutics (Ticker: APRE), holds ― shares in Vor Biopharma (Ticker: VOR).
Profitable Transactions
4 out of 6 Profitable Transactions
Average Return
-17.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Fouad Namouni holds in companies
Most Profitable Insider Trade
Stock:
Blueprint Medicines
(BPMC)
(BPMC)
Rating:Informative Sell
Date:Oct 07, 2021 - Oct 07, 2022
Return:+40.10%
The most profitable trade made by Fouad Namouni
Fouad Namouni's Trading History
Aprea Therapeutics
Jul 01, 2021
Director
Uninformative Buy
―
$3.52K
Blueprint Medicines
Jul 21, 2025
―
Uninformative Buy
―
$0.00
Vor Biopharma
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Fouad Namouni's performance on stock
You May Also Like
Fouad Namouni insider profile FAQ
What is the percentage of profitable transactions made by Fouad Namouni?
The percentage of profitable transactions made by Fouad Namouni is 67%.
What is the average return per transaction made by Fouad Namouni?
The average return per transaction made by Fouad Namouni is -17.10%.
What stocks does Fouad Namouni hold?
Fouad Namouni holds: APRE, BPMC, VOR stocks.
What was Fouad Namouni’s latest transaction?
Fouad Namouni latest transaction was an Uninformative Buy of ―.
What was Fouad Namouni's most profitable transaction?
Fouad Namouni’s most profitable transaction was an Informative Sell of BPMC stock on October 7, 2021. The return on the trade was 40.10%.
What is Fouad Namouni's role in Aprea Therapeutics?
Fouad Namouni's role in Aprea Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.